Rapamycin tested in RCT of elderly adults for immune, cognitive, and functional effects.
This was a translational RCT investigating whether rapamycin, an FDA-approved immunosuppressant, could improve immune responsiveness, cognition, and functional outcomes in elderly adults aged 70-95. The abstract describes the trial design and rationale based on preclinical findings in mice but does not report results, sample size, or effect sizes from the human trial.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 4, 2018 · Discovered: Sep 19, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Elderly persons aged 70-95
- Primary outcome
- Improvement in life functions; effects on immune responsiveness, cognitive function, and functional consequences
- Effect size
- —
- Significance
- Not reported
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Dec 4, 2018
Sources
Primary source
Source versions
Assessment history
9/24/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.